Lupin Profits Slump But US Approvals Pick-Up In Sight
This article was originally published in PharmAsia News
Lupin has reported a sharp decline in net profits for the second quarter, with sales inching up only marginally, hurt by a slowdown in product approvals in the US and a lack of "material" launches there. But the outlook seems brighter.
Register for our free email digests: